| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | MOLBREEVI (molgramostim inhalation solution) autoimmune pulmonary alveolar proteinosis (autoimmune PAP) | PDUFA | — | Biologics | Rare Diseases | ||
PDUFA Date example | MOLBREEVI (molgramostim inhalation solution) autoimmune pulmonary alveolar proteinosis (autoimmune PAP) | PDUFA | — | Biologics | Rare Diseases | ||
PDUFA Date example | MOLBREEVI (molgramostim inhalation solution) autoimmune pulmonary alveolar proteinosis (autoimmune PAP) | PDUFA | — | Biologics | Rare Diseases |
Recent Updates
Recently added Catalysts
Savara, Inc.$5.83
+0.05 (+0.87%)
D 37Pipeline Score Richly Valued Pharma · Commercial
Market Cap
1.03 B
EPS
-0.56
P/E Ratio
-
Value Trade
9.51 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
23.40 M
Operating CF
-33.05 M
Total Assets
221.65 M
Total Liabilities
45.61 M
Equity
176.04 M
D/E Ratio
12,345
-2.52 %
Week
-4.92 %
1 Month
-11.46 %
3 Month
7.73 %
6 Month
206.1 %
5 Year
-99.77 %
All Time
Cash Data
Cash Position
202.77 M
Monthly Burn
11.02 M
Runway
17.2 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
1.90 M
52 Week Range
1.89 - 7.01
% held by Insiders
47.97 %
% held by Institutions
58.93 %
Enterprise Value
856.07 M
Total Shares
203.37 M
Short %
23.12 %
Float Shares
130.57 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D37
Pipeline Score $44M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 50%
Micro Cap (rank 453 of 905)
Percentile RankSavara, Inc. faces pipeline headwinds (37/100), with $138M risk-adjusted pipeline value, led by molgramostim in Mycobacterium Infections, Nontuberculous (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molgramostim Small molecule | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | NCT04544293 | 58% | $97M | ACTIVE NOT_RECRUITING | 308 | SLOW | B (71) | May 30, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | 2025-08-21 | |||
Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | 2025-08-21 | |||
Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | 2025-08-21 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SVRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SVRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SVRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SVRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SVRA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SVRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SVRASavara Announces New Employment Inducement Grant
Savara has announced a new employment inducement grant. Details regarding the specifics of the grant and its implications for the company were not provided in the article. This announcement may indicate efforts to attract talent within the organization. However, further information is needed to assess the full impact of this grant.
Read more →SVRASavara Announces Chief Financial and Administrative Officer Transition
Savara has announced a transition in its Chief Financial and Administrative Officer position. The article does not provide specific details regarding the reasons for the transition or the implications for the company. This change reflects ongoing adjustments within the company's leadership structure.
Read more →SVRASavara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara has announced its participation in the upcoming 2026 Jefferies Global Healthcare Conference. This event will provide an opportunity for the company to engage with investors and discuss its strategic initiatives. Further details regarding the presentation or topics to be covered have not been disclosed.
Read more →SVRASavara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara presented new biomarker data from the IMPALA-2 Phase 3 clinical trial of Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS International Conference 2026. The presentation highlighted important findings that could impact future research and treatment strategies for aPAP. Further details on the data and its implications were discussed during the conference.
Read more →SVRASavara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara presented long-term efficacy and safety data from the ongoing IMPALA-2 Phase 3 clinical trial regarding Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP). The data was shared during a recent presentation. Further details on the findings were not provided in the article.
Read more →SVRASavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara has announced new exercise capacity data from the IMPALA-2 Phase 3 clinical trial of Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP). The data highlights the potential benefits of Molgramostim in improving exercise capacity for patients. Further details on the results and implications were not provided in the announcement.
Read more →SVRASavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara Inc. announced its participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference, scheduled for May 19th at NASDAQ headquarters in New York. The management team will engage in a fireside chat, which will be available for live streaming and later replay. Savara focuses on rare respiratory diseases, with its lead program, MOLBREEVI, in Phase 3 development.
Read more →SVRASavara Reports First Quarter Financial Results and Provides Business Update
Savara has released its financial results for the first quarter, along with a business update. The report outlines the company's current financial standing and strategic direction moving forward. Specific details regarding revenue, expenses, and future plans were shared, although no significant changes or developments were highlighted.
Read more →SVRASavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara has announced its participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference. This event provides a platform for the company to engage with investors and discuss its ongoing projects and developments. Further details about the conference and Savara's presentation are yet to be disclosed.
Read more →SVRASavara Announces New Employment Inducement Grant - April 17, 2026
Savara Inc. announced the grant of inducement awards to 24 new employees on April 14, 2026. The awards include stock options, restricted stock units, and performance stock units, aimed at encouraging employee retention. These equity awards are part of Savara's 2021 Inducement Equity Incentive Plan and are tied to the employees' continued employment.
Read more →SVRASavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. announced that the FDA has extended the review period for its molgramostim Biologics License Application (BLA) for autoimmune pulmonary alveolar proteinosis by three months, now set for November 22, 2026. This extension follows the submission of additional information by the company, which the FDA deemed a major amendment. The FDA did not express any safety or efficacy concerns.
Read more →SVRASavara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
Savara Inc. will present new data from the Phase 3 IMPALA-2 clinical trial of molgramostim at the ATS International Conference in May 2026. The presentations include an oral presentation on exercise improvements in aPAP patients and two poster presentations discussing long-term efficacy and biomarker relationships. The company will also host an industry theater focusing on aPAP advancements.
Read more →SVRASavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara has announced that the FDA has extended the review period for its Biologics License Application for Molgramostim, intended for treating Autoimmune Pulmonary Alveolar Proteinosis. This extension may lead to delays in the approval process, impacting patients who are in need of this treatment. The specific reasons for the extension have not been disclosed.
Read more →SVRASavara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara has announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted its Marketing Authorisation Application (MAA) for MOLBREEVI*, aimed at treating Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP). This acceptance marks a significant step forward for the company in bringing this treatment to market. The decision highlights the potential for addressing an unmet medical need in this area.
Read more →SVRASavara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara has announced that the European Medicines Agency has validated its Marketing Authorization Application for MOLBREEVI, a treatment for Autoimmune Pulmonary Alveolar Proteinosis. This validation marks a crucial advancement in the drug's approval process. The company aims to provide a solution for patients suffering from this rare autoimmune disease.
Read more →SVRASavara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Savara Inc. reported its fourth quarter and full year 2025 financial results, highlighting advancements in the MOLBREEVI program. The company has filed a Biologics License Application (BLA) with a PDUFA date set for August 22, 2026. Despite a net loss increase, Savara maintains a strong cash position and is preparing for a global commercial launch. The FDA has granted several designations to MOLBREEVI, indicating its potential in treating autoimmune pulmonary alveolar proteinosis.
Read more →SVRASavara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. has received a Day 74 Letter from the FDA regarding its MOLBREEVI Biologics License Application, indicating that no Advisory Committee meeting is planned. The company has submitted a Marketing Authorization Application to the EMA and is on track to submit to the U.K.'s MHRA by the end of Q1 2026. MOLBREEVI is positioned as a potential first-in-class treatment for autoimmune pulmonary alveolar proteinosis.
Read more →SVRASavara Announces Participation in 2026 Citizens Life Sciences Conference
Savara Inc. has announced its participation in the 2026 Citizens Life Sciences Conference, where members of the management team will engage in a fireside chat. The event is scheduled for March 11th in Miami, FL, and will be available via live webcast. Savara focuses on rare respiratory diseases, with its lead program, MOLBREEVI, in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Read more →SVRASavara Announces Participation in Upcoming February 2026 Investor Healthcare Conferences
Savara Inc. has announced its participation in two upcoming investor healthcare conferences in February 2026. The management team will engage in one-on-one meetings and fireside chats at the Guggenheim Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. These events aim to enhance investor relations and showcase Savara's focus on rare respiratory diseases.
Read more →SVRASavara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Savara Inc. has amended its loan agreement with Hercules Capital, allowing for up to $75 million in additional funding contingent on FDA approval of its therapy, MOLBREEVI. This amendment, combined with a previously announced $75 million royalty financing, positions Savara with approximately $150 million in non-dilutive capital for the launch of MOLBREEVI. The company aims for potential approval in 3Q 2026 and plans to submit marketing applications in Europe and the U.K. by early 2026.
Read more →SVRASAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Savara, Inc. on behalf of long-term stockholders after a class action complaint was filed against the company. The lawsuit claims that Savara's board may have breached their fiduciary duties by failing to disclose critical information regarding the MOLBREEVI Biologics License Application. Following the FDA's refusal to file letter, indicating a lack of completeness in the application, Savara's stock plummeted nearly 32%. Investors are encouraged to contact the law firm to discuss their legal rights and options.
Read more →SVRASavara Announces New Employment Inducement Grant - January 16, 2026
Savara Inc. announced the grant of inducement awards to two new employees on January 15, 2026. The awards include options to purchase 17,500 shares and restricted stock units covering 12,500 shares, aimed at incentivizing the new hires. These grants are part of the Savara Inc. 2021 Inducement Equity Incentive Plan, aligning with the company's focus on rare respiratory diseases.
Read more →SVRASafe Harbor Statement Savara Inc. All Rights Reserved. Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a description of historical fact are forward-looking statement
Savara Inc. has issued a Safe Harbor Statement concerning its development of MOLBREEVI, an investigational product for autoimmune pulmonary alveolar proteinosis (PAP). The company outlines the potential health benefits and risks along with the development timeline; however, it warns that actual results may significantly differ from current expectations. The statement emphasizes the challenges of obtaining regulatory approval and the uncertainties surrounding funding and clinical trials. Additionally, there is a notable absence of approved treatments for autoimmune PAP, highlighting the significance of Savara's efforts in this area.
Read more →SVRASavara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. has resubmitted its Biologics License Application for MOLBREEVI to the FDA, aiming for approval to treat autoimmune pulmonary alveolar proteinosis. The company has requested Priority Review for the application. MOLBREEVI has previously received several designations from regulatory agencies, highlighting its potential in treating this rare lung disease.
Read more →SVRASavara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Savara Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Matt Pauls will present and hold one-on-one meetings. The event is scheduled for January 14 at the Westin St. Francis in San Francisco. Savara's lead program, MOLBREEVI, is currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Read more →SVRASavara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Savara Inc. announced that the European Patent Office intends to grant a patent for the liquid formulation of MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis (PAP). This patent will enhance the company's intellectual property rights in Europe until 2041. Additionally, MOLBREEVI has received various designations from regulatory bodies, indicating its potential as a first-in-class therapy. The company plans to resubmit its Biologics License Application (BLA) to the FDA soon.
Read more →SVRASavara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Savara Inc. announced that the European Patent Office has granted a patent for the drug-device combination of MOLBREEVI and the eFlow® Nebulizer System, jointly held with PARI. This patent, valid until March 2043, enhances the protection of MOLBREEVI for treating autoimmune pulmonary alveolar proteinosis (PAP). The company is preparing for regulatory submissions in the U.S. and Europe.
Read more →SVRASavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SVRA
Savara Inc. is facing a legal challenge following a class action lawsuit due to alleged violations of securities laws. Shareholders who purchased shares between March 7, 2024, and May 23, 2025, are encouraged to contact the DJS Law Group for participation. The lawsuit claims that Savara made false statements regarding its Biologics License Application (BLA) for MOLBREEVI, specifically failing to provide sufficient details on chemistry and manufacturing. This deficiency raises concerns about the likelihood of FDA approval.
Read more →SVRASAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
A class action lawsuit has been initiated against Savara Inc. (SVRA) in the U.S. District Court for the Eastern District of Pennsylvania. The lawsuit pertains to Savara's failure to disclose issues with the MOLBREEVI Biologics License Application (BLA), which has resulted in an FDA refusal to file letter due to insufficient completeness. Investors who acquired securities between March 7, 2024, and May 23, 2025, are urged to contact a law firm for assistance. The company's stock experienced a significant decline following the announcement of the FDA's decision.
Read more →SVRASAVARA CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before November 7th
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Savara Inc., concerning securities purchased between March 7, 2024, and May 23, 2025. Investors have until November 7, 2025, to apply as lead plaintiffs. The lawsuit originates from claims that Savara failed to disclose critical issues with its MOLBREEVI Biologics License Application, leading to a refusal to file letter from the FDA. Following this announcement, Savara's stock experienced a significant decline.
Read more →SVRASavara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SVRA
Savara Inc. is embroiled in a lawsuit filed by The Gross Law Firm on behalf of shareholders, alleging that the company made materially false or misleading statements regarding its product, MOLBREEVI. The complaint contends that the company's failure to provide adequate information about the treatment's chemistry, manufacturing, and controls contributed to the unlikeliness of FDA approval. This situation raises concerns about potential delays in the approval process and the necessity for Savara to raise additional capital. Shareholders are encouraged to register for the class action before the November 7, 2025 deadline.
Read more →SVRASAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED
Savara Inc. announced a public offering of 23,809,524 shares of common stock priced at $4.20 per share, generating total gross proceeds of $130 million. The proceeds will be used to support the clinical development of MOLBREEVI for autoimmune pulmonary alveolar proteinosis and related commercialization activities. The offering is set to close on October 31, 2025, pending customary conditions. The company has granted underwriters the option to purchase additional shares as part of the offering.
Read more →SVRASAVARA ANNOUNCES $75M ROYALTY FUNDING AGREEMENT WITH RTW TO SUPPORT THE POTENTIAL LAUNCH OF MOLBREEVI* IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) - RTW Committed $75M in Launch Funding, Subject to U.S.
Savara Inc. announced a $75 million royalty funding agreement with RTW Investments to support the expected launch of its drug MOLBREEVI for autoimmune pulmonary alveolar proteinosis, pending FDA approval. CEO Matt Pauls highlighted the strategic significance of the non-dilutive financing, which will enhance the company's commercial capabilities. The investment reflects confidence in MOLBREEVI, which has shown potential in clinical trials to address an unmet medical need. The deal also includes a tiered royalty structure tied to the annual net sales of the drug in the U.S.
Read more →SVRASAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders of the November 7th Deadline in the Filed Class Action Lawsuit
A class action lawsuit has been filed against Savara Inc. in the U.S. District Court for the Eastern District of Pennsylvania. The suit relates to allegations of undisclosed issues regarding the MOLBREEVI Biologics License Application (BLA), including the FDA's doubts about its completeness. Following a May announcement that the FDA issued a refusal to file letter due to these concerns, the company's stock price plummeted by 31.69%. Investors have until November 7, 2025, to apply for lead plaintiff status in this lawsuit.
Read more →SVRASAVARA CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Investors of the November 7th Deadline in the Filed Class Action Lawsuit
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Savara Inc. for allegedly failing to disclose important information about the MOLBREEVI Biologics License Application. The lawsuit covers securities purchased between March 7, 2024, and May 23, 2025, with a deadline for lead plaintiff applications set for November 7, 2025. The complaint highlights issues with the BLA's completeness, leading to a refusal to file letter from the FDA, which subsequently resulted in a significant drop in Savara's stock price.
Read more →SVRASavara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA
Savara Inc. is being sued for alleged violations of securities laws by shareholders who purchased shares between March 4, 2024, and May 23, 2025. The complaint claims that the company provided misleading statements about the submission of its biologics license application (BLA) for MOLBREEVI, a treatment for pulmonary alveolar proteinosis. Investors are concerned that the FDA is unlikely to approve the BLA in its current form, which could lead to capital raising needs for the company. Shareholders have until November 7, 2025, to register for participation in the class action.
Read more →SVRASAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th Deadline
A class action lawsuit has been initiated against Savara Inc. following allegations of undisclosed issues with its MOLBREEVI Biologics License Application (BLA) during the class period from March 7, 2024, to May 23, 2025. The lawsuit claims that the company failed to inform investors about the likelihood of FDA approval due to insufficient information in the BLA. Following the issuance of a refusal to file (RTF) letter by the FDA, Savara's stock price plummeted by nearly 32%. Interested investors are urged to connect with the plaintiff's law firm before the November 7, 2025, deadline.
Read more →SVRASavara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA
Savara Inc. is being sued for securities law violations related to its pulmonary alveolar proteinosis treatment, MOLBREEVI. Allegations include the issuance of misleading statements regarding the treatment's development and expected FDA approval. The class period for affected shareholders is from March 4, 2024, to May 23, 2025, with a deadline for lead plaintiff registration on November 7, 2025. Investors are encouraged to participate in the class action to seek potential recovery for losses incurred due to the alleged omissions and misrepresentations.
Read more →SVRASAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Savara Inc. for failing to adequately disclose issues with the MOLBREEVI Biologics License Application, which is now unlikely to receive FDA approval in its current form. Investors must respond before the November 7, 2025, deadline to be appointed as lead plaintiff in the case. The lawsuit follows a significant drop in Savara's stock price after the FDA issued a refusal to file letter regarding the application, raising concerns about the company's financial stability and the need for additional capital.
Read more →SVRASAVARA ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Savara, Inc. To Contact the Firm Before the November 7th Deadline Regarding the Filed Class Action Lawsuit
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Savara Inc. for failing to disclose critical information related to the MOLBREEVI Biologics License Application during the specified class period. The lawsuit stems from the FDA's refusal to file the application due to inadequacies in data pertaining to the therapy's chemistry and manufacturing controls. Following this news, Savara's stock experienced a notable decline, dropping 31.69%. Investors have a deadline of November 7, 2025, to respond to this legal action.
Read more →SVRASavara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Savara Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
Savara Inc. is facing a class action lawsuit due to allegations that it made misleading statements about its MOLBREEVI biologics license application (BLA). Following an FDA refusal to file the BLA, Savara's stock price fell sharply by nearly 32%. Investors affected by the decline have until November 7, 2025, to file as lead plaintiffs in the lawsuit. The case centers on claims that Savara inadequately disclosed issues related to chemistry, manufacturing, and controls that could hinder regulatory approval and compel the company to raise additional capital.
Read more →SVRASAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the November 7th Deadline in The Savara Class Action Lawsuit
Savara Inc. is facing a class action lawsuit due to allegations of not disclosing crucial information related to the MOLBREEVI Biologics License Application. This lapse in communication has led to doubts over the FDA's approval of the application and potential financial implications for the company. Investors who bought shares between March 7, 2024, and May 23, 2025, can apply to be lead plaintiffs in the case by the November 7, 2025 deadline. The lawsuit follows a significant stock price drop of 31.69% following the announcement of the FDA's refusal to file letter, raising concerns among stockholders.
Read more →SVRASavara Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights – SVRA
Savara Inc. is currently involved in a class action securities fraud lawsuit filed by Levi & Korsinsky, LLP. The lawsuit centers on allegations that the company made misleading statements regarding its treatment, MOLBREEVI, for pulmonary alveolar proteinosis. Plaintiffs claim that Savara did not disclose critical information affecting the likelihood of FDA approval and the company’s timeline for submission. Investors affected by this issue have until November 7, 2025, to seek recovery and potentially serve as lead plaintiffs in the case.
Read more →SVRASAVARA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Savara Inc. and Encourages Investors to Contact the Firm
Savara Inc. is facing a class action lawsuit filed by Bragar Eagel & Squire on behalf of investors who suffered losses from March 7, 2024, to May 23, 2025. The lawsuit stems from alleged failures to disclose critical information regarding the MOLBREEVI Biologics License Application (BLA) and its subsequent refusal to file by the FDA. This has led to a significant drop in Savara's stock price, indicating investor dissatisfaction and concerns over the company's regulatory status. Investors have until November 7, 2025, to apply as lead plaintiffs in the lawsuit.
Read more →SVRASAVARA RECEIVES REFUSAL TO FILE (RTF) LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE BIOLOGICS LICENSE APPLICATION (BLA) FOR MOLBREEVI* TO TREAT PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (A
Savara Inc. received a Refusal to File (RTF) letter from the FDA regarding its Biologics License Application (BLA) for MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis. The FDA found the application incomplete and has requested additional Chemistry, Manufacturing, and Controls (CMC) data. Despite this setback, the company emphasizes that the RTF was not related to safety concerns and underscores its confidence in addressing the agency's requests before resubmitting the BLA. Previous designations for the drug remain unaffected.
Read more →SVRASAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HERCULES CAPITAL Includes $30M at Close to Refinance Existing Debt Facility LANGHORNE, PA
Savara Inc. has announced a loan and security agreement with Hercules Capital for up to $200 million. This financing will bolster the company's financial position as it prepares for the potential FDA approval of MOLBREEVI, an innovative therapy for autoimmune pulmonary alveolar proteinosis (aPAP). The agreement guarantees an initial $30 million, aimed at refinancing existing debt. Savara is on track to submit a Marketing Authorization Application in Europe this year, further emphasizing their commitment to bringing novel treatments to market.
Read more →SVRACorporate Overview Developing New Therapies for Rare Respiratory Diseases January 2025 Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. ("Savara" or the "Company") cautions you that statements in this p
Savara Inc. is developing MOLBREEVI, an investigational therapy for Autoimmune Pulmonary Alveolar Proteinosis (aPAP). While the treatment offers hope to patients with limited options, it has not yet received FDA approval. The company's forward-looking statements indicate plans for commercialization and disease awareness campaigns, yet they also acknowledge the risks of unforeseen challenges and financial uncertainties that may affect development timelines and product success. Savara advises stakeholders to avoid undue reliance on these predictions as actual outcomes may vary significantly.
Read more →SVRASAVARA ANNOUNCES PRICING OF $100.0
Savara Inc. announced an underwritten offering of 26,246,720 shares of its common stock, pricing the shares at $3.81 each, which is expected to raise approximately $100 million. The offering is set to close on July 1, 2024, pending customary closing conditions. Major investors include Bain Capital Life Sciences and Wellington Management, among others. The funds from this offering are anticipated to support the company's continued development of its products focused on rare respiratory diseases.
Read more →SVRASAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3 CLINICAL TRIAL IN AUTOIMMUNE PULMONAR
Savara Inc. announced that its molgramostim nebulizer solution achieved statistically significant results for the primary endpoint and multiple secondary endpoints in the Phase 3 IMPALA-2 clinical trial for autoimmune pulmonary alveolar proteinosis (aPAP). The trial demonstrated a durable effect on lung function over 48 weeks, positioning molgramostim as a potential first approved treatment for aPAP in the U.S. and Europe. While the drug was well-tolerated, some side effects, including a higher incidence of COVID-19, were noted.
Read more →SVRACorporate Overview Developing New Therapies for Rare Respiratory Diseases January 2024 Safe Harbor Statement Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a descri
Savara Inc. is focused on developing molgramostim for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) and is currently conducting a pivotal Phase 3 trial with expectations for top-line data release by the end of the second quarter of 2024. The company has reported promising efficacy and safety data from earlier trials and has received multiple designations to facilitate development. However, Savara warns that their forward-looking statements involve risks and uncertainties, and actual outcomes may differ substantially from the projections made.
Read more →SVRASAVARA ANNOUNCES PRICING OF $80 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED
Savara Inc. has announced the pricing of an underwritten offering of 21 million shares of its common stock, expected to raise approximately $80 million. The shares are priced at $3.00 each, with the option for certain investors to purchase pre-funded warrants at $2.999. The offering is set to close on July 17, 2023, and is supported by prominent investors and underwriters. This funding aims to bolster Savara's clinical initiatives, particularly for its lead product, molgramostim, in development for rare respiratory diseases.
Read more →SVRASavara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a description of historical fact are forward-looking statement
Savara Inc. has provided an update on the status of its product candidate molgramostim for treating autoimmune pulmonary alveolar proteinosis (aPAP). The company emphasizes that recent trial outcomes assert potential benefits, though they acknowledge that their forward-looking statements are subject to risks and uncertainties. Savara's strong financial position, supported by $115M in cash, is expected to fund operations beyond pivotal data read-outs and regulatory filings. Despite positive developments, the company cautions against over-reliance on these statements due to various factors impacting clinical trial success.
Read more →SVRASafe Harbor Statement Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the
Savara Corporate Presentation (NASDAQ: SVRA) March 2021 Exhibit 99.1 Safe Harbor Statement Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identi
Read more →SVRASAVARA PROVIDES PIPELINE AND BUSINESS UPDATE Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman an
SAVARA PROVIDES PIPELINE AND BUSINESS UPDATE Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses to Align with
Read more →SVRASAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer AUSTIN, TX
SAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer AUSTIN, TX Sept. 11, 2020 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced tha
Read more →SVRASAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP
SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q1 2021 AUSTIN, TX August
Read more →SVRASAVARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP AUSTIN, TX
SAVARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP AUSTIN, TX May 7, 2020 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financ
Read more →SVRASAVARA REPORTS FOURTH QUARTER / YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exp
SAVARA REPORTS FOURTH QUARTER / YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex Company Planning an Additional Phase
Read more →SVRASAVARA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR MOLGRADEX FOR THE TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (aPAP) AUSTIN, TX
SAVARA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR MOLGRADEX FOR THE TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (aPAP) AUSTIN, TX Dec. 30, 2019 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (
Read more →SVRASAVARA ANNOUNCES PRIVATE PLACEMENT OF $26.8 MILLION, WITH TOTAL POTENTIAL PROCEEDS OF $75.0
SAVARA ANNOUNCES PRIVATE PLACEMENT OF $26.8 MILLION, WITH TOTAL POTENTIAL PROCEEDS OF $75.0 MILLION AUSTIN, TX December 20, 2019 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement w
Read more →SVRASAVARA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Pro
SAVARA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis (aPAP) AUSTIN, TX November 7, 2019 Savara Inc. (Nasdaq: SVRA), an o
Read more →SVRADisclosures The Impala trial was sponsored by Savara Pharmaceuticals I receive grant funding from the US National Institutes of Health I have consulted for: Boehringer Ingelheim, CSL Behring, Genzyme, Gilead, Grifols, GS
Safety and Efficacy of Inhaled GM-CSF (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis - The IMPALA Trial - Baseline Data and Blinded Treatment Period Results Bruce C. Trapnell, M.D. Translational Pulmonary Science Center Cincinnati Children's Hospital Medical Center
Read more →SVRASAVARA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Molgradex aPAP Program: Continue with Regulatory Interactions, Expect FDA Written Responses to Type C Meeting in October Anticipate Filing
SAVARA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Molgradex aPAP Program: AUSTIN, TX August 8, 2019 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2019 and pro
Read more →SVRASavara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP) The study did not meet its primary endpoint of alveolar-arterial oxygen gradient ( A-
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP) AUSTIN, TX June 12, 2019 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced top line data from IMPALA, a pivotal Phas
Read more →SVRASAVARA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Top Line Results from Pivotal Phase 3 IMPALA Study Expected in June 2019 Molgradex Received Fast Track Designation by FDA for Autoimmune Pu
SAVARA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Top Line Results from Pivotal Phase 3 IMPALA Study Expected in June 2019 Molgradex Received Fast Track Designation by FDA for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Announce Indication
Read more →SVRASAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE On-Track to Report Top Line Results from Pivotal Phase 3 IMPALA Study at End of Q2 2019 AUSTIN, TX
SAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE On-Track to Report Top Line Results from Pivotal Phase 3 IMPALA Study at End of Q2 2019 AUSTIN, TX Mar. 13, 2018 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today re
Read more →SVRASavara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
Savara Inc. has provided updates on its pivotal Phase 3 studies, IMPALA and AVAIL, focusing on treatments for autoimmune pulmonary alveolar proteinosis and MRSA lung infections in cystic fibrosis patients, respectively. The company expects to report top line results from IMPALA by the end of Q2 2019 and aims for a BLA submission in early 2020. However, enrollment challenges have been noted in the AVAIL study, particularly among younger participants.
Read more →SVRASavara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM
Savara Inc. has announced interim results from the OPTIMA Phase 2a clinical study of Molgradex for treating nontuberculous mycobacterial lung infections. The study shows promising efficacy signals, particularly in patients with Mycobacterium avium complex infections. Safety assessments indicate a generally favorable profile, although some serious adverse events were reported. The study duration has been extended to 48 weeks to observe more robust anti-infective effects.
Read more →SVRASavara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th
Savara Inc. will participate in the Evercore ISI HealthCONx Conference on November 27, 2018. CEO Rob Neville is scheduled for a fireside chat at the event in Boston. Interested parties can access a live audio webcast on Savara's website, with an archived version available for 30 days post-event. The company focuses on developing treatments for orphan lung diseases.
Read more →SVRASavara Reports Third Quarter 2018 Financial Results and Provides Business Update
Savara Inc. reported its third quarter 2018 financial results, highlighting progress in its lead candidate Molgradex and upcoming pivotal clinical studies. The company aims to address unmet needs in orphan lung diseases while expanding its pipeline through acquisitions. Despite an increased net loss and rising R&D expenses, Savara maintains a strong cash position to support its initiatives.
Read more →SVRASavara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018
Savara Inc. will announce its third quarter 2018 financial results on November 7, 2018. The company will host a conference call at 5:30 p.m. ET to discuss these results and provide a business update. Interested parties can access the call via phone or through a live webcast on Savara's website.
Read more →SVRASavara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM
Interim Results Expected in Q4 2018 AUSTIN, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target enrollment of 30 patients in OPTIMA, a Phase 2a clinical study evaluating its lead product ca
Read more →SVRASavara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
Savara Inc. has completed enrollment of 135 patients in its pivotal Phase 3 IMPALA study for Molgradex, aimed at treating autoimmune pulmonary alveolar proteinosis (aPAP). The study is a significant step towards providing the first FDA-approved treatment for this rare lung disease. Top line results are anticipated in Q2 2019, with ongoing safety studies planned.
Read more →SVRASavara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data
Savara Inc. has provided updates on patient enrollment for its Molgradex studies, with the IMPALA Phase 3 trial nearing its target of 135 patients and the OPTIMA Phase 2a trial also close to completion. Both studies are expected to report topline data in Q2 2019, with interim results from OPTIMA anticipated in Q4 2018. The company continues to advance its pipeline for orphan lung diseases.
Read more →SVRASavara Becomes Inaugural Foundation Sponsor of the PAP Foundation
Savara Inc. has announced a global partnership with the PAP Foundation, becoming its inaugural sponsor. This collaboration aims to enhance education and support for individuals affected by Pulmonary Alveolar Proteinosis (PAP). Savara will assist in expanding the PAP patient registry and supporting the 1st Annual National PAP Education Day, promoting awareness and community engagement.
Read more →SVRASAVARA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES POSITIVE BUSINESS UPDATE Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018 AeroVanc Phase 3 AVAIL study enrollment on track for
SAVARA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES POSITIVE BUSINESS UPDATE Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018 AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019 Molgradex Phase 2a OPTIMA study e
Read more →SVRASavara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018
AUSTIN, Texas, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its second quarter 2018 financial results on Thursday, August 9, 2018. Savara management will also host a conference call for investors beg
Read more →SVRASavara Announces Pricing of Public Offering of Common Stock
AUSTIN, Texas, July 26, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $11.50 per share. The expected gross proc
Read more →SVRASavara Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. The offering is subject to m
Read more →SVRASAVARA PROVIDES POSITIVE UPDATE ON DEVELOPMENT AND COMMERCIAL PREPARATIONS OF MOLGRADEX, INCLUDING EXPANSION INTO NTM IN CF Acquires assets of Cardeas and Announces Appointment of A. Bruce Montgomery, M.D., As Strategic
SAVARA PROVIDES POSITIVE UPDATE ON DEVELOPMENT AND COMMERCIAL PREPARATIONS OF MOLGRADEX, INCLUDING EXPANSION INTO NTM IN CF Acquires assets of Cardeas and Announces Appointment of A. Bruce Montgomery, M.D., As Strategic Advisor AUSTIN, TX July 25, 2018 Savara Inc. (Nasdaq: SVR
Read more →SVRASavara to Ring Nasdaq Stock Market Opening Bell on July 23rd
AUSTIN, Texas, July 23, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, announced today that Rob Neville, CEO of Savara, alongside key members of senior management, company directors, and employees, will ring the Nasdaq Stock Market Opening Bel
Read more →SVRASavara Joins Russell 3000 Index
AUSTIN, Texas, June 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the company has been added to the broad-market Russell 3000 Index. “In the little more than one year since transitioning to the public markets, Savara
Read more →SVRASavara to Present at JMP Securities 2018 Life Sciences Conference on June 20th
AUSTIN, Texas, June 13, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob Neville, will present at the JMP Securities 2018 Life Sciences Conference on Wednesday June 20, 2018 at 3:30
Read more →SVRASavara Provides Update on Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria Infection
AUSTIN, Texas, May 29, 2018 (GLOBE NEWSWIRE) -- Savara, Inc. (NASDAQ:SVRA), an orphan lung disease company, today provided an update on two case reports exploring the use of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of Mycobacterium a
Read more →SVRASavara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 17th
AUSTIN, Texas, May 11, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the Company's Chief Executive Officer, Rob Neville, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference on Tuesday May 15th, 20
Read more →SVRASAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018 AeroVanc Phase 3 AVAIL study enrollment on track for completio
SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018 AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019 Molgradex Phase 2a OPTIMA study enrollment
Read more →SVRASAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Anticipating completion of enrollment in Molgradex Phase 3 IMPALA study in Q3 2018 Anticipating completion of enrollment in
SAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Anticipating completion of enrollment in Molgradex Phase 3 IMPALA study in Q3 2018 Anticipating completion of enrollment in AeroVanc Phase 3 AVAIL study in Q1 2019 Anticipating com
Read more →SVRASAVARA REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - Anticipating complete enrollment in the Molgradex Phase 3 IMPALA study in Q1 2018 - Initiating Phase 2a study of Molgradex for the treatm
SAVARA REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - Anticipating complete enrollment in the Molgradex Phase 3 IMPALA study in Q1 2018 - Initiating Phase 2a study of Molgradex for the treatment of NTM in early 2018 - Expecting top-line results fro
Read more →SVRASAVARA ANNOUNCES EXPANSION OF MOLGRADEX DEVELOPMENT TO INCLUDE TREATMENT OF NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG INFECTION Company Anticipates Phase 2a Clinical Trial Will Begin in Early 2018 AUSTIN, TX
SAVARA ANNOUNCES EXPANSION OF MOLGRADEX DEVELOPMENT TO INCLUDE TREATMENT OF NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG INFECTION Company Anticipates Phase 2a Clinical Trial Will Begin in Early 2018 AUSTIN, TX October 24, 2017 - Savara Inc. (NASDAQ: SVRA), an orphan lung disease c
Read more →SVRASAVARA REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE On track to initiate Phase 3 study of AeroVanc in Q3 2017 On track to complete enrollment of Aironite Phase 2 INDIE study in Q4 2017 On tr
SAVARA REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE On track to initiate Phase 3 study of AeroVanc in Q3 2017 On track to complete enrollment of Aironite Phase 2 INDIE study in Q4 2017 On track to complete enrollment in Molgradex Phase 3 IMPALA st
Read more →SVRASAVARA ANNOUNCES CLOSING OF MERGER WITH MAST THERAPEUTICS Commences Trading on Nasdaq Capital Market on
SAVARA ANNOUNCES CLOSING OF MERGER WITH MAST THERAPEUTICS Commences Trading on Nasdaq Capital Market on April 28, 2017 Under Ticker Symbol SVRA Conference Call Scheduled for Tuesday May 2nd, 2017 at 4:30 p.m. ET / 3:30 p.m. CT AUSTIN, TX April 27, 2017 Savara Inc. (NASDAQ: SVR
Read more →SVRASafe Harbor Statements Forward Looking Statements. Savara cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use
Corporate presentation APRIL 2017 Safe Harbor Statements Forward Looking Statements. Savara cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as "expect
Read more →SVRAMAST THERAPEUTICS ANNOUNCES POSSIBLE ADJOURNMENT OF SPECIAL STOCKHOLDERS MEETING TO SOLICIT ADDITIONAL VOTES FOR MERGER WITH SAVARA Over 95% of Votes Cast to Date are in Favor of the Merger, but More Votes Are Necessary
MAST THERAPEUTICS ANNOUNCES POSSIBLE ADJOURNMENT OF SPECIAL STOCKHOLDERS MEETING TO SOLICIT ADDITIONAL VOTES FOR MERGER WITH SAVARA Over 95% of Votes Cast to Date are in Favor of the Merger, but More Votes Are Necessary to Achieve Quorum and Approval of All Required Proposals S
Read more →SVRAMAST REMINDS STOCKHOLDERS TO VOTE FOR THE PROPOSED MERGER WITH SAVARA • Of the Votes Received to Date, More than 90% Are Voting in Favor of the Merger • More Votes Are Needed to Reach 50% of the Outstanding
MAST REMINDS STOCKHOLDERS TO VOTE FOR THE PROPOSED MERGER WITH SAVARA SAN DIEGO - April 17, 2017 - Mast Therapeutics, Inc. (NYSE MKT: MSTX) would like to thank its stockholders for their support of the proposed merger with Savara Inc. ("Savara") and remind those stockholders th
Read more →SVRALEADING INDEPENDENT PROXY ADVISORY FIRMS ISS AND GLASS LEWIS RECOMMEND MAST THERAPEUTICS STOCKHOLDERS VOTE "FOR"
LEADING INDEPENDENT PROXY ADVISORY FIRMS ISS AND GLASS LEWIS RECOMMEND MAST THERAPEUTICS STOCKHOLDERS VOTE "FOR" THE PROPOSED MERGER AND RELATED PROPOSALS SAN DIEGO - April 11, 2017 - Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that Institutional Shareholder Servi
Read more →SVRAMAST THERAPEUTICS AND SAVARA ANNOUNCE APPROVAL TO LIST COMMON STOCK ON THE NASDAQ CAPITAL MARKET Special Meeting of Mast Therapeutics Stockholders to Be Held on
MAST THERAPEUTICS AND SAVARA ANNOUNCE APPROVAL TO LIST COMMON STOCK ON THE NASDAQ CAPITAL MARKET Special Meeting of Mast Therapeutics Stockholders to Be Held on April 21, 2017 SAN DIEGO, CA and AUSTIN, TX - April 10, 2017 - Mast Therapeutics, Inc. (NYSE MKT: MSTX) and Savara In
Read more →SVRAMAST THERAPEUTICS SETS DATE FOR SPECIAL MEETING OF STOCKHOLDERS TO VOTE ON PROPOSED MERGER WITH SAVARA Special Meeting To Be Held on
MAST THERAPEUTICS SETS DATE FOR SPECIAL MEETING OF STOCKHOLDERS TO VOTE ON PROPOSED MERGER WITH SAVARA Special Meeting To Be Held on April 21, 2017 SAN DIEGO, CA and AUSTIN, TX - March 16, 2017 - Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today it has set a date for a s
Read more →SVRAMAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2016
MAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS SAN DIEGO - March 6, 2017 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 20
Read more →SVRAShareholder Update / Q4 Shareholder Brief Wednesday
Shareholder Update / Q4 Shareholder Brief Wednesday, January 25, 2017 As you likely know, a merger agreement between Savara, Inc. ("Savara") and Mast Therapeutics, Inc. ("Mast") was executed on January 6, 2017, with the closing of the transaction expected to occur by the second
Read more →SVRAEvent Name: Mast-Savara Conference Call Event Date
Event Name:Mast-Savara Conference Call Event Date:January 9, 2017 Operator: Welcome to the Mast-Savara conference call. An audio webcast of this call is available on the Investor's section of Mast's website at www.masttherapeutics.com. This call is subject to copyright proper
Read more →SVRAMAST THERAPEUTICS AND SAVARA SIGN MERGER AGREEMENT Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call S
MAST THERAPEUTICS AND SAVARA SIGN MERGER AGREEMENT Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call Scheduled for Monday, January 9 at 8:30 a.m. ET / 5:30 a.m.
Read more →SVRAMAST THERAPEUTICS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS Conference Call Scheduled Today at 4:30pm ET / 1:30pm
MAST THERAPEUTICS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS Conference Call Scheduled Today at 4:30pm ET / 1:30pm PT SAN DIEGO - November 8, 2016 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the
Read more →SVRASafe Harbor Statement This presentation includes forward-looking statements about our business prospects, financial position, and development of investigational new drugs for therapeutic use in humans. Any statement that
Corporate Overview October 19, 2016 Exhibit 99.1 Safe Harbor Statement This presentation includes forward-looking statements about our business prospects, financial position, and development of investigational new drugs for therapeutic use in humans. Any statement that is not a
Read more →SVRASafe Harbor Statement This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any statement that is
Corporate Overview September 12, 2016 Exhibit 99.1 Safe Harbor Statement This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any statement that is not a s
Read more →SVRAMAST THERAPEUTICS REPORTS SECOND QUARTER 2016
MAST THERAPEUTICS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS SAN DIEGO - August 9, 2016 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported financial resul
Read more →SVRAMAST THERAPEUTICS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS AND RECENT HIGHLIGHTS Completed enrollment in Phase 3 EPIC study of vepoloxamer in sickle cell disease Announced positive top-line results from Phase 2a stud
MAST THERAPEUTICS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS AND SAN DIEGO - May 6, 2016 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported financial resul
Read more →SVRAMAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2015
MAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS SAN DIEGO - March 14, 2016 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported
Read more →SVRAMAST ANNOUNCES AMENDMENT TO LOAN AND SECURITY AGREEMENT WITH HERCULES capital
MAST ANNOUNCES AMENDMENT TO LOAN AND SECURITY AGREEMENT WITH SAN DIEGO - February 29, 2016 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today announced that it has en
Read more →SVRAMAST THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2A STUDY OF AIR001 IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) CONDUCTED AT MAYO CLINIC Study met its primary endpoint; AIR001
MAST THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2A STUDY OF AIR001 IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) CONDUCTED AT MAYO CLINIC Study met its primary endpoint; AIR001 was generally well-tolerated, with no treatment-related ser
Read more →SVRAMAST THERAPEUTICS' AIR001 SELECTED BY THE HEART FAILURE CLINICAL RESEARCH NETWORK FOR EVALUATION IN A 100-PATIENT MULTICENTER PHASE 2
MAST THERAPEUTICS' AIR001 SELECTED BY THE HEART FAILURE CLINICAL RESEARCH NETWORK FOR EVALUATION IN A 100-PATIENT MULTICENTER PHASE 2 STUDY SAN DIEGO - February 1, 2016 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage thera
Read more →SVRAForward Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any statement th
Corporate Overview January 11, 2016 Brian M. Culley, Chief Executive Officer Exhibit 99.1 Forward Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic
Read more →SVRAMAST THERAPEUTICS PROVIDES BUSINESS UPDATE Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%; top-line data anticipated Q2 2016 Enrollment in Phase 2a study of AIR001 in HFp
MAST THERAPEUTICS PROVIDES BUSINESS UPDATE SAN DIEGO - January 7, 2016 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today provided a business update. "We are pleased
Read more →SVRAMAST THERAPEUTICS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Conference Call Scheduled Today at 4:30pm ET / 1:30pm
MAST THERAPEUTICS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Conference Call Scheduled Today at 4:30pm ET / 1:30pm PT SAN DIEGO - November 12, 2015 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sea
Read more →SVRAMAST ANNOUNCES AMENDMENT TO LOAN AND SECURITY AGREEMENT WITH HERCULES technology growth capital Hercules funds second advance of $10 million; total funding now $15 million Amendment allows for deferral or elimination of
MAST ANNOUNCES AMENDMENT TO LOAN AND SECURITY AGREEMENT WITH HERCULES technology growth capital SAN DIEGO - September 30, 2015 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST)
Read more →SVRAForward-Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any statement th
NYSE MKT: MSTX Corporate Overview September 15, 2015 Exhibit 99.1 Forward-Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any state
Read more →SVRAMAST THERAPEUTICS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Conference Call Scheduled for Thursday, August 13 th at 8:30am ET / 5:30am
MAST THERAPEUTICS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Conference Call Scheduled for Thursday, August 13th at 8:30am ET / 5:30am PT SAN DIEGO - August 12, 2015 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecul
Read more →SVRAmstx-ex991_201507216.pptx.htm NYSE MKT: MSTX Corporate Overview
NYSE MKT: MSTX Corporate Overview July 21, 2015 Forward-Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any statement that is not a
Read more →SVRAmstx-ex991_2015062554.pptx.htm NYSE MKT: MSTX Corporate Overview
NYSE MKT: MSTX Corporate Overview June 25, 2015 Forward-Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any statement that is not a
Read more →SVRAMAST THERAPEUTICS REPORTS FIRST QUARTER 2015
MAST THERAPEUTICS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS SAN DIEGO - May 11, 2015 - Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for
Read more →SVRAMAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2014
MAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS SAN DIEGO March 24, 2015 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel
Read more →SVRANYSE MKT: MSTX Corporate Overview March 2,, 2015 Forward-Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR00
Forward-Looking Statements includes forward-looking statements about our business prospects, financial position, and development of vepoloxamer and AIR001 for therapeutic use in humans. Any statement that is not a statement of historical fact should be considered a forward-look
Read more →SVRANYSE MKT: MSTX 2 Forward Looking Statements This presentation includes forward looking statements about our business prospects, financial position, and development of MST 188 and AIR001 for therapeutic use in humans. Any
No approved medications pulmonary vascular resistance pulmonary capillary wedge pressure right atrial pressure NYSE MKT: MSTX Three Phase 1 studies: Established MTD and safe dose level Confirmed conversion of nitrite to nitric oxide (NO) Acute improvements in hypoxia induced pulm
Read more →SVRABIO Investor Forum Brandi L. Roberts, CFO
Investor Forum Brandi L. Roberts, CFO October 7, 2014 Forward-Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of MST-188 and AIR001 for therapeutic use in humans. Any statement that is no
Read more →SVRANYSE MKT: MSTX Rodman Renshaw 16th Annual Investment Conference Brian M. Culley, CEO
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54. 31 Upcoming News Events Cash/investments at 6/30/14: $46.4 million Market capitalization: ~$80 million* Shares outstanding: ~126 million* Average daily volume (3 mo): ~885,000* No debt
Read more →SVRANYSE MKT: MSTX Canaccord Genuity 34th Annual Growth Conference Brian M. Culley, CEO
J Am Coll Cardiol 2009; 54: S43-S54. 30 Upcoming News Events Cash/investments at 6/30/14: $46.4 million Market capitalization: ~$75 million* Shares outstanding: ~121 million* Average daily volume (3 mo): ~1.2 million* No debt 31 * As of August 11, 2014 MSTX Financial Overview A L
Read more →SVRANYSE MKT: MSTX Corporate Overview Brian M. Culley, CEO
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54. Cash/investments at 3/31/14: $49.6 million Market capitalization: ~$73 million* Shares outstanding: ~116 million* Average daily volume (3 mo): ~2.1 million* No debt Evaluating strategi
Read more →SVRAA Brief History of MST-188 Definitions RheothRx A first-generation product with unpurified , excipient-grade poloxamer 188 as the active ingredient. Associated with elevated serum creatinine. MST-188 (formerly known as A
A Brief History of MST-188 Early Development: The CytRx Corporation/Burroughs Wellcome Alliance Poloxamer 188 is a well-studied compound. It was originally used as an emulsifying agent in topical wound cleansers and parenteral nutrition products. However, the therapeutic use o
Read more →SVRAMAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2013
MAST THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS SAN DIEGO March 26, 2014 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013. 2013 was a year of great progress for Mast
Read more →SVRACorporate Overview
Forward-Looking Statements This presentation includes forward-looking statements about our business prospects, financial position, and development of MST-188 and AIR001 for therapeutic use in humans. Any statement that is not a statement of historical fact should be considered
Read more →SVRAADVENTRX
ADVENTRX PRICES PUBLIC OFFERING OF STOCK SAN DIEGO November 11, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the pricing of an underwritten public offering of 21,250,000 shares of its common stock and warrants exercisable for up to 10,625,000 additional
Read more →SVRAADVENTRX COMPLETES ACQUISITION OF SYNTHRX SAN DIEGO (
ADVENTRX COMPLETES ACQUISITION OF SYNTHRX SAN DIEGO (April 11, 2011) ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has completed its acquisition of SynthRx, Inc., now a wholly owned subsidiary of ADVENTRX. SynthRx s lead product candidate is a novel,
Read more →SVRAADVENTRX PHARMACEUTICALS ANNOUNCES CAPITAL RAISE OF $22.5
ADVENTRX PHARMACEUTICALS ANNOUNCES CAPITAL RAISE OF $22.5 MILLION SAN DIEGO January 7, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has entered into definitive agreements to sell 8,184,556 units in a registered direct offering to RA Capital Mana
Read more →SVRAADVENTRX ANNOUNCES 6-MONTH STABILITY DATA RESULTS FOR ANX-530 SAN DIEGO (
ADVENTRX ANNOUNCES 6-MONTH STABILITY DATA RESULTS FOR ANX-530 SAN DIEGO (May 3, 2010) ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or ExelbineTM, manufactured a
Read more →SVRAADVENTRX TO RESUBMIT ANX-530 NDA IN THE FOURTH QUARTER OF 2010 SAN DIEGO (
ADVENTRX TO RESUBMIT ANX-530 NDA IN THE FOURTH QUARTER OF 2010 SAN DIEGO (April 27, 2010) - ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, based on information received from the U.S. Food and Drug Administration (FDA), the Company plans to resubmit its
Read more →SVRAADVENTRX PHARMACEUTICALS SUBMITS ANX-530 NEW DRUG APPLICATION SAN DIEGO (
ADVENTRX PHARMACEUTICALS SUBMITS ANX-530 NEW DRUG APPLICATION SAN DIEGO (January 4, 2010) ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate
Read more →Competitive Position
How SVRA ranks across every disease it competes inCompetitive Position is a premium feature
See how SVRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial